The tweet was deleted by the author.
But we saved everything 🙂.
CVRx is spotlighting its Barostim device therapy at ISHLT2026, emphasizing its potential to improve exercise capacity and quality of life for individuals with heart failure.
The company advocates combining guideline-directed medical therapy (GDMT) with Barostim, targeting the neurohormonal pathway to achieve greater patient outcomes compared to GDMT alone. Attendees are invited to explore the device at the CVRx booth on the final day of the event.
CVRx previously showcased Barostim at ACC26, presenting data on improved exercise capacity in heart failure patients compared to guideline-directed medical therapy alone, according to company presentations earlier this year. The firm also reported preliminary Q1 2026 revenue of $14.7 to $14.8 million, representing an estimated 20 percent increase from the prior year period, as outlined in recent results. These updates follow ongoing efforts to expand the use of Barostim in heart failure care.